Dr. Irina Kaverina's lab focuses on understanding how the structural components of cells, specifically microtubules and their associated motor proteins, influence the function of insulin-producing beta cells. Through their research, the lab aims to uncover mechanisms that regulate insulin secretion, which is critical in managing blood sugar levels and preventing conditions like diabetes. By using advanced microscopy and modeling techniques, the lab investigates how these cellular components can be manipulated to improve beta cell function and glucose homeostasis.

Dr. Jeffrey M. Spraggins' lab at Vanderbilt University focuses on understanding the molecular basis of kidney diseases and Alzheimer's disease through advanced imaging techniques. By utilizing cutting-edge multimodal imaging and spatially resolved molecular technologies, the lab aims to identify key pathways in these diseases, helping to uncover potential biomarkers and therapeutic targets. The research combines expertise in nephrology, analytical chemistry, and cell biology, making it a hub for innovative biomedical discovery.

Dr. Qiangjun Zhou's lab at Vanderbilt University focuses on understanding the tiny structures in the brain that help neurons communicate efficiently. By studying the molecular building blocks of synapses, particularly in relation to neurodevelopmental disorders like autism and schizophrenia, the lab aims to uncover how genetic mutations disrupt brain function. This research is not only crucial for gaining insight into these disorders but also for developing potential new treatments.

Dr. Bruce D. Carter's lab at Vanderbilt University studies how signals affect the development of the nervous system, particularly focusing on the processes that lead to the degeneration of neurons and connections. The lab aims to understand the mechanisms behind neuronal cell death and how they may contribute to neurological disorders such as Alzheimer's disease and autism. By exploring the role of specific receptors and molecular signals, their research seeks to uncover new insights into nervous system development and disease.

Dr. Ethan Lippmann's lab focuses on developing innovative delivery methods for RNA-based therapies to treat conditions like Alzheimer's disease. Their work centers on using specially designed lipid conjugates to enhance the targeting of specific cells in the brain, allowing for effective silencing of genes associated with the disease. By studying how these substances interact within the brain's structure, the lab aims to improve therapeutic outcomes for patients.

Dr. Vsevolod V. Gurevich's lab focuses on understanding the molecular interactions of a protein called arrestin-1 with rhodopsin, which is crucial for vision. Researchers in this lab study how different forms of rhodopsin affect arrestin-1 binding and explore ways to create modified versions of arrestin-1 that could help treat vision disorders related to defects in rhodopsin phosphorylation. The work involves a mix of molecular biology techniques and innovative labeling methods to discover new proteins that interact with arrestin-1.

Dr. Andrea Page-Mccaw's lab at Vanderbilt University studies how tissues repair themselves after injury. The team uses fruit fly models to investigate the repair mechanisms of epithelial tissues and basement membranes, which are crucial for organ structure. Their research aims to uncover the fundamental processes of tissue repair to inform clinical therapies for wounds and injuries when normal healing fails.

Dr. Yi Ren's lab at Vanderbilt University is delving into the mechanisms of mRNA nuclear export, focusing on how the SARS-CoV-2 Nsp1 protein inhibits this process to enhance viral replication. The lab aims to uncover how this viral protein interacts with host cellular machinery and how understanding these interactions can lead to new antiviral strategies. Their research combines techniques from biochemistry, cell biology, and structural biology to provide insights into both fundamental cellular processes and viral pathogenesis.

Dr. Thilo Womelsdorf's lab at Vanderbilt University studies how certain drugs can improve cognitive abilities and motivation. They specifically focus on a new type of drug designed to work with receptors in the brain that influence behavior and thought processes, particularly concerning conditions like schizophrenia. The research involves both behavioral tests on primates and measurements of brain chemistry to understand how these drugs can help enhance mental functions without unpleasant side effects.